Benzodiazepine metabolism: An analytical perspective

Current Drug Metabolism

Volumn 9, Issue 8, 2008, Pages 827-844

  Mandrioli, Roberto ^a   Mercolini, Laura ^a   Raggi, Maria Augusta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Analytical methods; Anxiolytics; Benzodiazepines; Cytochrome P450; Liquid chromatography; Sample pre treatment; Sedative hypnotics; UDP glucuronosyltransferase

Indexed keywords

ALEPAM; ALPRAVECS; ALPRAZIG; ALPRAZOLAM; AMPRENAVIR; ANTIFUNGAL AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BRIXOPAN; BROMAZEPAM; BROTIZOLAM; CALMEPAM; CLARITHROMYCIN; CLOTIAZEPAM; COMPENDIUM; CREOSEDIN; CURCUMIN; DIAZEPAM; DURAZANIL; ERYTHROMYCIN; ETIZOLAM; FLORMIDAL; FLUCONAZOLE; FLUNITRAZEPAM; FLUOXETINE; FRONTAL; HIPNOSEDON; HOMOFENAZINE; HYPNOTIC SEDATIVE AGENT; ILMAN; INSOM; IPNOVEL; ISONIAZID; LIMBIAL; LORAZEPAM; LORZEM; MIDAZOLAM; MIDAZOLAM MALEATE; MODAFINIL; MURELAX; NILIUM; NIMBISAN; NIRAVAM; NOVEPAM; NOVODORM; OXASCAND; OXAZEPAM; PHENOBARBITAL; RANITIDINE; RIFAMPICIN; RITONAVIR; RIZEN; SEDEKOPAN; SEROTONIN UPTAKE INHIBITOR; SLIPIREM; SOMALIUM; TIENOR; TRANQUIRIT; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VULBEGAL; ZELIREM; ZOTRILAX; AZEPINE DERIVATIVE; DRUG DERIVATIVE;

ACCURACY; AGGRESSION; ALCOHOLIC BEVERAGE; ANALYTIC METHOD; ANXIETY DISORDER; AREA UNDER THE CURVE; BEDTIME DOSAGE; CONTINUOUS INFUSION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; EVENING DOSAGE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MASS SPECTROMETRY; MENTAL DISEASE; NONHUMAN; PANIC; PHARMACOGENETICS; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE DRUG DOSE; SPECTROPHOTOMETRY; VIOLENCE; ANIMAL; METABOLISM;

ALPRAZOLAM; ANIMALS; ANTI-ANXIETY AGENTS; AZEPINES; BENZODIAZEPINES; BROMAZEPAM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAZEPAM; HUMANS; LORAZEPAM; MASS SPECTROMETRY; MIDAZOLAM; TRIAZOLAM;

EID: 58149328817     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920008786049258     Document Type: Review

References (190)

1. Greenblatt, D.J. Pharmacology of benzodiazepine hypnotics (1992) J. Clin. Psychiatry, 53(Suppl. 1), 7-13.
2. Nemeroff, C.B. Anxiolytics: past, present, and future agents (2003) J. Clin. Psychiatry, 64(Suppl. 3), 3-6.
3. Charney, D.S.; Mihic, S.J. and Harris, R.A. Hypnotics and Sedatives (2005) in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th Edition, (Brunton, L.; Lazo, J.; Parker, K. Eds.), McGraw-Hill, Cloumbus, pp. 401-428.
4. Erman, M.K. Influence of pharmacokinetic profiles on safety and efficacy of hypnotic medications (2006) J. Clin. Psychiatry, 67(Suppl. 13), 9-12.
5. Chouinard, G.; Lefko-Singh, K. and Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem (1999) Cell. Mol. Neurobiol., 19(4), 533-552.
6. Paton, C.; Banham, S. and Whitmore, J. Benzodiazepines in schizophrenia. Is there a trend towards long-term prescribing? (2000) Psychiat. Bull., 24, 113-115.
7. Birkenhäger, T.K.; Moleman, P. and Nolen, W.A. Benzodiazepines for depression? A review of the literature (1995) Int. Clin. Psychopharmacol., 10(3), 181-195.
8. Gaillard, R.; Ouanas, A.; Spadone, C.; Llorca, P.-M.; Loo, H. and Bayle, F.-J. Benzodiazépines et schizophrénie, revue de la littérature (2006) Encephale, 32(6), 1003-1010.
9. Verster, J.C. and Volkerts, E.R. Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature (2004) CNS Drug Rev., 10(1), 45-76.
10. Smith, R.B.; Kroboth, P.D.; Vanderlugt, J.T.; Phillips, J.P. and Juhl, R.P. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration (1984) Psychopharmacology, 84, 452-456.
11. Erdman, K.; Stypinski, D.; Combs, M.; Witt, P.; Stiles, M. and Pollock, S. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet (2007) Pharmacotherapy, 27(8), 1120-1124.
12. Kaplan, G.B.; Greenblatt, D.J.; Ehrenberg, B.L.; Goddard, J.E.; Harmatz, J.S. and Shader, R.I. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects (1998) J. Clin. Pharmacol., 38(1), 14-21.
13. Yasui, N.; Otani, K.; Kaneko, S.; Ohkubo, T.; Osanai, T.; Sugawara, K.; Chiba, K. and Ishizaki, T. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism (1996) Clin. Pharmacol. Ther., 59(5), 514-519.
14. Williams, J.A.; Ring, B.J.; Cantrell, V.E.; Jones, D.R.; Eckstein, J.; Ruterbories, K.; Hamman, M.A.; Hall, S.D. and Wrighton, S.A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7 (2002) Drug Metab. Dispos., 30(8), 883-891.
15. Hirota, N.; Ito, K.; Iwatsubo, T.; Green, C.E.; Tyson, C.A.; Shimada, N.; Suzuki, H. and Sugiyama, Y. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans (2001) Biopharm. Drug Dispos., 22(2), 53-71
16. Yasui, N.; Kondo, T.; Furukori, H.; Kaneko, S.; Ohkubo, T.; Uno, T.; Osanai, T.; Sugawara, K. and Otani, K. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam (2000) Psychopharmacology, 150(2), 185-190.
17. Park, J.-Y.; Kim, K.-A.; Park, P.-W.; Lee, O.-J.; Kang, D.-K.; Shon, J.-H.; Liu, K.-H. and Shin, J.-G. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects (2006) Clin. Pharmacol. Ther., 79(6), 590-599.
18. Venkatakrishnan, K. and Gibbs, M.A. CYP3A5 polymorphism and alprazolam pharmacokinetics/pharmacodynamics (2006) Clin. Pharmacol. Ther., 80(6), 719-720.
19. Park, J.-Y.; Kim, K.-A. and Shin, J.-G. Reply to CYP3A5 polymorphism and alprazolam pharmacokinetics/pharmacodynamics (2006) Clin. Pharmacol. Ther., 80(6), 720-720.
20. Wennerholm, A.; Allqvist, A.; Svensson, J.-O.; Gustafsson, L.L.; Mirghani, R.A. and Bertilsson, L. Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α - and 4-hydroxy metabolites in healthy subjects (2005) Eur. J. Clin. Pharmacol., 61(2), 113-118.
21. Lau, C.E. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration (1999) Drug Metab. Dispos., 27(8), 855-859.
22. Gupta, B.; Chopra, S.C.; Gupta, C.; Mahajan, R.; Uppal, B.; Minocha, K.B. Effects of fluoxetine, risperidone and alprazolam on pharmacokinetics of lithium in patients with psychiatric illness (2006) Indian J. Pharmacol., 38(2), 133-134.
23. Calvo, G.; Garcia-Gea, C.; Luque, A.; Morte, A.; Dal-Re, R. and Barbanoj, M. Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers (2004) J. Clin. Psychopharmacol., 24(3), 268-276.
24. Preskorn, S.H.; Greenblatt, D.J. and Harvey, A.T. Lack of effect of sertraline on the pharmacokinetics of alprazolam (2000) J. Clin. Psychopharmacol., 20(5), 585-586.
25. Suzuki, Y.; Shioiri, T.; Muratake, T.; Kawashima, Y.; Sato, S.; Hagiwara, M.; Inoue, Y.; Shimoda, K. and Someya, T. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles (2003) Eur. J. Clin. Pharmacol., 58(12), 829-833.
26. Amchin, J.; Zarycranski, W.; Taylor, K.P.; Albano, D. and Klockowski, P.M. Effect of venlafaxine on the pharmacokinetics of alprazolam (1998) Psychopharmacol. Bull., 34(2), 211-219.
27. Arold, G.; Donath, F.; Maurer, A.; Diefenbach, K.; Bauer, St.; Henneicke-von Zepelin, H.-H.; Friede, M. and Roots, I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract (2005) Planta Med., 71(4), 331-337.
28. Toyo'oka, T.; Kumaki, Y.; Kanbori, M.; Kato, M. and Nakahara, Y. Determination of hypnotic benzodiazepines (alprazolam, estazolam, and midazolam) and their metabolites in rat hair and plasma by reversed-phase liquidchromatography with electrospray ionization mass spectrometry (2003) J. Pharm. Biomed., 30(6), 1773-1787.
29. Crouch, D.J.; Rollins, D.E.; Canfield, D.V.; Andrenyak, D.M. and Schulties, J.E. Quantitation of alprazolam and alphahydroxyalprazolam in human plasma using liquid chromatography electrospray ionization MS-MS (1999) J. Anal. Toxicol., 23, 479-485.
30. Allqvist, A.; Wennerholm, A.; Svensson, J.-O. and Mirghani, R.A. Simultaneous quantification of alprazolam, 4- and α - hydroxyalprazolam in plasma samples using liquid chromatography mass spectrometry (2005) J. Chromatogr. B, 814(1), 127-131.
31. Jin, L. and Lau, C.E. Determination of alprazolam and its major metabolites in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats (1994) J. Chromatogr. B, 654(1), 77-83.
32. Hall, J.; Naranjo, C.A.; Sproule, B.A.; Herrmann, N. Pharmacokinetic and Pharmacodynamic Evaluation of the Inhibition of Alprazolam by Citalopram and Fluoxetine (2003) J. Clin. Psychopharmacol., 23(4), 349-357.
33. Yajima, T.; Ohno, T.; Nakamura, K. and Nakamura, K. Effects of bromazepam on responses of mucosal blood flow in the gastrointestinal tract and of gastric motility to stimulation of the amygdala and hypothalamus in conscious cats (1984) Folia Pharmacol. Jpn., 83(3), 237-248.
34. Ohtani, Y.; Kotegawa, T.; Tsutsumi, K.; Morimoto, T.; Hirose, Y. and Nakano, S. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: An application of electroencephalography as the pharmacodynamic method (2002) J. Clin. Pharmacol., 42(2), 183-191.
35. van Harten, J.; Holland, R.L. and Wesnes, K. Influence of multipledose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomized, crossover study (1992) Eur. Neuropsychopharmacol., 2(3), 381-381.
36. Oda, M.; Kotegawa, T.; Tsutsumi, K.; Ohtani, Y.; Kuwatani, K. and Nakano, S. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers (2003) Eur. J. Clin. Pharmacol., 59(8-9), 615-619.
37. "Lexotan" Product Information, approved 6 October 2004, amended 22 February 2007. Available through http://www.pbs.gov.au/pi/ roplexot10207.pdf (last access: 20 July 2008).
38. Schwartz, M.A.; Postma, E.; Kolis, S. and Leon, A.S. Metabolites of bromazepam, a benzodiazepine, in the human, dog, rat, and mouse (2006) J. Pharm. Sci., 62, 1776-1779.
39. Lerner, F.E.; Schere, D.; Batafarano, N.; Casas, F. and Glancszpigel, R. Comparative bioavailability of two oral formulations of bromazepam in healthy volunteers (2001) Arzneimittel Forschung, 51(12), 955-958.
40. Funk, F.; Canclini, C. and Geisser, P. Interactions between iron(III)-hydroxide polymaltose complex and commonly used medications. Laboratory studies in rats (2007) Arzneimittel Forschung, 57(6a), 370-375.
41. Heizmann, P.; Geschke, R. and Zinapold, K. Determination of bromazepam in plasma and its main metabolites in urine by reversed phase high-performance liquid chromatography (1984) J. Chromatogr., 310, 129-137.
42. Albu, F.; Georgita, C.; Tache, F.; Mutihac, L.; Medvedovici, A. and David, V. Considerations on MS/MS Detection of Bromazepam after Liquid Chromatographic Separation from Plasma Samples: Application to a Bioequivalence Study (2007) J. Liquid Chromatogr. R.T., 30(18), 2699-2715.
43. Saraiva Goncalves, J.C.; Monteiro, T.M.; de Miranda Neves, C.S.; da Silva Gram, K.R.; Volpato, N.M.; Silva, V.A.; Caminha, R.; do Rocio Bencke Goncalves, M.; Dos Santos, F.M.; Estolano Da Silveira, G. and Noel, F. On-line solid-phase extraction coupled with high-performance liquid chromatography and tandem mass spectrometry (SPE-HPLC-MS-MS) for quantification of bromazepam in human plasma: an automated method for bioequivalence studies (2005) Ther. Drug Monit., 27(5), 601-607.
44. Andraus, M. H.; Wong, A.; Silva, O.A.; Wada, C.Y.; Toffleto, O.; Azevedo, C.P. and Salvadori, M.C. Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: Application to a bioequivalence study (2004) J. Mass Spectrom., 39(11), 1348-1355.
45. Arendt, R.; Ochs, H.R. and Greenblatt, D. J. Electron capture GLC analysis of the thienodiazepine clotiazepam. Preliminary pharmacokinetic studies (1982) Arzneimittel Forschung, 32(4), 453-455.
46. Niwa, T.; Shiraga, T.; Ishii, I.; Kagayama, A. and Takagi, A. Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs (2005) Biol. Pharm. Bull., 28(9), 1711-1716.
47. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y. and Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians (1994) J. Pharmacol. Exp. Ther., 270, 414-423.
48. Greenblatt, D.J.; Divoll, M.K.; Soong, M.H.; Boxenbaum, H.G.; Harmatz, J.S. and Shader, R.I. Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam (1988) J. Clin. Pharmacol., 28(9), 853-859.
49. Baselt, R.C. and Cravey, R.H. (1995) in Disposition of toxic drugs and chemicals in man, 4th ed., Chemical Toxicology Institute, Foster City, 1995, p. 211.
50. Saito, K.; Sakai, N.; Kim, H.-S.; Ishizuka, M.; Kazusaka, Akio. and Fujita S. Strain differences in diazepam metabolism at its three metabolic sites in Sprague-Dawley, Brown Norway, Dark Agouti, and istar strain rats (2004) Drug Metab. Dispos., 32(9), 959-965.
51. Sakai, N.; Saito, K.; Kim, H.-S.; Kazusaka, A.; Ishizuka, M.; Funae, Y. and Fujita, S. Importance of CYP2D3 in polymorphism of diazepam p-hydroxylation in rats (2005) Drug Metab. Dispos., 33(11), 1657-1660.
52. Yang, T.J.; Krausz, K.W.; Shou, M.; Yang, S.K.; Buters, J.T.M.; Gonzalez, F.J. and Gelboin, H.V. Inhibitory monoclonal antibody to human cytochrome P450 2B6 (1998) Biochem. Pharmacol., 55(10), 1633-1640.
53. Yang, T.J.; Shou, M.; Korzekwa, K.R.; Gonzalez, F.J.; Gelboin, H.V. and Yang, S.K. Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam (1998) Biochem. Pharmacol., 55(6), 889-896.
54. Mei, Q.; Tang, C.; Assang, C.; Lin, Y.; Slaughter, D.; Rodrigues, A.D.; Baillie, T.A.; Rushmore, T.H. and Shou, M. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism (1999) J. Pharmacol. Exp. Ther., 291(2), 749-759.
55. Yang, T.J.; Krausz, K.W.; Sai, Y.; Gonzalez, F.J. and Gelboin, H.V. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism (1999) Drug Metab. Dispos., 27(1), 102-109.
56. Fukasawa, T.; Suzuki, A. and Otani, K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines (2007) J. Clin. Pharm. Ther., 32(4), 333-341.
57. Zhou, H.-H. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase (2001) Clin. Chim. Acta, 313(1-2), 203-208.
58. Qin, X.-P.; Xie, H.-G.; Wang, W.; He, N.; Huang, S.-L.; Xu, Z.-H.; Ou-Yang, D.-S.; Wang, Y.-J. and Zhou, H.-H. Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects (1999) Clin. Pharmacol. Ther., 66(6), 642-646.
59. Inomata, S.; Nagashima, A.; Itagaki, F.; Homma, M.; Nishimura, M.; Osaka, Y.; Okuyama, K.; Tanaka, E.; Nakamura, T.; Kohda, Y.; Naito, S.; Miyabe, M. and Toyooka, H. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia (2005) J. Clin. Pharm. Ther., 78(6), 647-655.
60. Klotz, U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications (2007) Clin. Pharmacokin., 46(4), 271-279.
61. de Haro, L.; Valli, M.; Bourdon, J.H.; Iliadis, A.; Hayek-Lanthois, M. and Arditti, J. Diazepam poisoning with one-month monitoring of diazepam and nordiazepam blood levels (2001) Vet. Hum. Toxicol., 43(3), 174-175.
62. Wagner, S.O.; Sams, R.A. and Podell, M. Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog (1998) J. Vet. Pharmacol. Ther., 21(5), 335-341.
63. Ozdemir, M.; Aktan, Y.; Boydag, B. S.; Cingi, M. I. and Musmul, A. Interaction between grapefruit juice and diazepam in humans (1998) Eur. J. Drug Metab. Pharmacokinet., 23(1), 55-59.
64. Reinach, B.; de Sousa, G.; Dostert, P.; Ings, R.; Gugenheim, J. and Rahmani, R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes (1999) Chem. Biol. Interact., 121(1), 37-48.
65. Desta, Z.; Soukhova, N.V.; Flockhart, D.A. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A (2001) Antimicrob. Agents Chemother., 45(2), 382-392.
66. Jones, H.M.; Hallifax, D. and Houston, J.B. Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes (2004) Drug Metab. Dispos., 32(5), 572-580.
67. Einer-Jensen, N. and Larsen, L. Local transfer of diazepam, but not of cocaine, from the nasal cavities to the brain arterial blood in rats (2000) Pharmacol. Toxicol., 87(6), 276-278.
68. Platt, S.R.; Randell, S.C.; Scott, K.C.; Chrisman, C.L.; Hill, R.C. and Gronwall, R.R. Comparison of plasma benzodiazepine concentrations following intranasal and intravenous administration of diazepam to dogs (2000) Am. J. Vet. Res., 61(6), 651-654.
69. Peinemann, F. and Daldrup, T. Severe and prolonged sedation in five neonates due to persistence of active diazepam metabolites (2001) Eur. J. Pediatr., 160(6), 378-381.
70. Parkinson, A.; Leonard, N.; Draper, A. and Ogilvie, B.W. On the Mechanism of Hepatocarcinogenesis of Benzodiazepines: evidence that Diazepam and Oxazepam are CYP2B Inducers in Rats, and both CYP2B and CYP4A Inducers in Mice (2006) Drug Metab. Rev., 38(1-2), 235-259.
71. Tanaka, E.; Terada, M.; Misawa, S. and Wakasugi, C. Simultaneous determination of twelve benzodiazepines in human serum using a new reversed-phase chromatographic column on a porous microspherical silica gel (1996) J. Chromatogr. B, 682, 173-178.
72. Mealey, K. and Boothe, D. Bioavailability of benzodiazepines following rectal administration of diazepam in dogs (1995) J. Vet. Pharmacol. Ther., 18, 72-74.
73. Reilly, P.E.B.; Thompson, D.A.; Mason, S.R. and Hooper, W.D. Cytochrome P450IIIA enzymes in rat liver microsomes: Involvement in C3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam (1990) Mol. Pharmacol. 37, 767-774.
74. "Depas" Product Information, approved 16 September 1999. Available through http://www.carloanibaldi.com/terapia/schede/ DEPAS.htm#SottoTitolo_11 (last access: 20 July 2008).
75. Niwa, T.; Shiraga, T.; Ishii, I.; Kagayama, A. and Takagi, A. Contribution of human hepatic cytochrome P450 isoforms to the metabolism of psychotropic drugs (2005) Biol. Pharm. Bull., 28(9), 1711-1716.
76. Araki, K.; Yasui-Furukori, N.; Fukasawa, T.; Aoshima, T.; Suzuki, A.; Inoue, Y.; Tateishi, T. and Otani, K. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism (2004) Eur. J. Clin. Pharmacol., 60(6), 427-430.
77. Fukasawa, T.; Yasui-Furukori, N.; Suzuki, A.; Inoue, Y.; Tateishi, T. and Otani, K. Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity (2005) Eur. J. Clin. Pharmacol., 61(11), 791-795.
78. Yue, Q.Y., Tomson, T. and Sawe, J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man (1994) Pharmacogenetics, 4, 193-198.
79. Kondo, S.; Fukasawa, T.; Yasui-Furukori, N.; Aoshima, T.; Suzuki, A.; Inoue, Y.; Tateishi, T. and Otani, K. Induction of the metabolism of etizolam by carbamazepine in humans (2005) Eur. J. Clin. Pharmacol., 61(3), 185-188.
80. Makino, T.; Inagaki, T.; Komatsu, K. and Kano, Y. Pharmacokinetic interactions between Japanese traditional Kampo medicine and modern medicine (IV). Effect of Kamisyoyosan and Tokisyakuyakusan on the pharmacokinetics of etizolam in rats (2005) Biol. Pharm. Bull., 28(2), 280-284.
81. Hikida, K., Inoue, Y., Nouchi, E. and Ohkura, Y. Determination of etizolam in human serum or plasma using automated column-switching high-performance liquid chromatography (1990) Jpn. J. Clin. Chem., 19, 354-359.
82. Ghanchi, F.D. and Khan, M.Y. Sublingual lorazepam as premedication in peribulbar anesthesia (1997) J. Cataract Refract. Surg., 23(10), 1581-1584.
83. Greenblatt, D.J. Clinical pharmacokinetics of oxazepam and lorazepam (1981) Clin. Pharmacokinet., 6(2), 89-105.
84. Chung, J.-Y.; Cho, J.-Y.; Yu, K.-S.; Kim, J.-R.; Jung, H.-R.; Lim, K.-S.; Jang, I.-J. and Shin, S-G. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers (2005) Clin. Pharmacol. Ther., 77(6), 486-494.
85. Sawamura, R.; Sato, H.; Kawakami, J. and Iga, T. Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro (2000) Biol. Pharm. Bull., 23(5), 669-671.
86. Papini, O.; Pereira Da Cunha, S.; Do Carmo Da Silva Mathes, A.; Bertucci, C.; Dantas Moises, E.C.; De Barros Duarte, L.; De Carvalho Cavalli, R. and Lanchote, V.L. Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples (2006) J. Pharm. Biomed., 40(2), 397-403.
87. Greenblatt, D.J.; Schillings, R.T.; Kyriakopoulos, A.A.; Shader, R.I.; Sisenwine, S.F.; Knowles, J.A. and Ruelius, H.W. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam (1976) Clin. Pharmacol. Ther., 20(3), 329-341.
88. Cohen-Mansfield, J.; Taylor, L.; Woosley, R.; Lipson, S.; Werner, P. and Billig, N. Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing home residents (2000) Ther. Drug Monit., 22(6), 688-694.
89. Arroliga, A.C.; Shehab, N.; McCarthy, K. and Gonzales, J.P. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults (2004) Crit. Care Med., 32(8), 1709-1714.
90. Al-Khafaji, A.H.; Dewhirst, W.E. and Manning, H.L. Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis (2002) Anesth. Analg., 94(6), 1583-1585.
91. Swart, E.L.; de Jongh, J.; Zuideveld, K.P.; Danhof, M.; Thijs, L.G. and Strack van Schijndel, R.J.M. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration (2005) Am. J. Kidney Dis., 45(2), 360-371.
92. Papini, O.; Bertucci, C.; Pereira da Cunha, S.; Guinaim dos Santos, N.A. and Lanchote, V.L. Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples (2006) J. Pharm. Biomed., 40(2), 389-396.
93. "Some Pharmaceutical Drugs", IARC Monographs vol. 66 (1996), p. 115. Available through http://www.inchem.org/documents/iarc/vol66/ oxazepam.html (Last access: 20 July 2008).
94. Mohler, H.; Okada, T.; Heitz, P. and Ulrich, J. Biochemical identification of the site of action of benzodiazepines in human brain by 3H-diazepam binding (1978) Life Sci., 22, 985-995.
95. Patel, M.; Tang, B.K. and Kalow, W. (S)-oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7 (1995) Pharmacogenetics 5, 43-49.
96. Court, M.H.; Duan, S.X.; Guillemette, C.; Journault, K.; Krishnaswamy, S.; Von Moltke, L.L. and Greenblatt, D.J. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9 (2002) Drug Metab. Dispos., 30(11), 1257-1265.
97. Court, M.H.; Hao, Q.; Krishnaswamy, S.; Bekaii-Saab, T.; Al-Rohaimi, A.; von Moltke, L.L. and Greenblatt, D.J. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver (2004) J. Pharmacol. Exp. Ther., 310(2), 656-665.
98. Greenblatt, D.J. Clinical pharmacokinetics of oxazepam and lorazepam (1981) Clin. Pharmacokinet., 6, 89-105.
99. Stockhaus, K. Physical dependence capacity of brotizolam in rhesus monkey. 2nd communications: primary dependence and barbital substitution (1986) Arzneimittel Forschung, 36(3a), 601-605.
100. Jochemsen, J.; Wesselman, J.G.J.; Hermans, J.; van Boxtel, C.J. and Breimer, D.D. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration (1983) Br. J. Clin. Pharmacol., 16(Suppl 2), 285-290.
101. Tokairin, T.; Fukasawa, T.; Yasui-Furukori, N.; Aoshima, T.; Suzuki, A.; Inoue, Y.; Tateishi, T. and Otani, K. Inhibition of the metabolism of brotizolam by erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in brotizolam metabolism (2005) Br. J. Clin. Pharmacol., 60(2), 172-175.
102. Osanai, T.; Ohkubo, T.; Yasui, N.; Kondo, T. and Kaneko, S. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam (2005) Br. J. Clin. Pharmacol., 58(5), 476-481
103. Ujiie, Y.; Fukasawa, T.; Yasui-Furukori, N.; Suzuki, A.; Tateishi, T. and Otani, K. Rifampicin Markedly Decreases Plasma Concentration and Hypnotic Effect of Brotizolam (2006) Ther. Drug Monit., 28(3), 299-302.
104. Osanai, T. and Ohkubo T. Development of high-performance liquid chromatographic method for determination of brotizolam on clinical pharmacokinetic study (2003) Anal. Lett., 36, 3025-3034.
105. Druid, H.; Holmgren, P. and Ahlner, J. Flunitrazepam: an evaluation of use, abuse and toxicity (2001) Forensic Sci. Int., 122(2-3), 136-141.
106. Cano, J. P.; Soliva, M.; Hartmann, D.; Ziegler, W. H. and Amrein, R. Bioavailability from various galenic formulations of flunitrazepam (1977) Arzneimittel Forschung, 27(12), 2383-2388.
107. Gafni, I.; Busto, U.E.; Tyndale, R.F.; Kaplan, H.L. and Sellers, E.M. The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo (2003) J. Clin. Psychopharmacol., 23(2), 169-175.
108. Kilicarslan, T.; Haining, R.L.; Rettie, A.E.; Busto, U.; Tyndale, R.F. and Sellers, E.M. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4 (2001) Drug Metab. Dispos., 29(4), 460-465.
109. Huang, W.; Lin, Y.S.; McConn, D.J. II,; Calamia, J.C.; Totah, R.A.; Isoherranen, N.; Glodowski, M. and Thummel, K.E. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism (2004) Drug Metab. Dispos., 32(12), 1434-1445.
110. Coller, J.K.; Somogyi, A.A. and Bochner, F. Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4 (1999) Xenobiotica, 29(10), 973-986
111. Peng, F.-C.; Chaing, H.-H.; Tang, S.-H.; Chen, P.-C. and Lu, S.-C. NADPH-Cytochrome P-450 Reductase is Involved in Flunitrazepam Reductive Metabolism in Hep G2 and Hep 3B Cells (2004) J. Toxicol. Environ. Health, 67(2), 109-124.
112. Kilicarslan, T. and Sellers, E.M. Lack of interaction of buprenorphine with flunitrazepam metabolism (2000) Am. J. Psychiatry, 157(7), 1164-1166.
113. Tanaka, E.; Nakamura, T.; Terada, T.; Shinozuka, T. and Honda, K. Lack of interaction of buprenorphine with flunitrazepam metabolism (2005) Basic Clin. Pharmacol. Toxicol., 96(1), 88-90.
114. Assaf, M.S. and Abdel-Rahman, M.S. Hepatotoxicity of flunitrazepam and alcohol in vitro (1999) Toxicol. in Vitro, 13(3), 393-401.
115. Negrusz, A.; Moore, C.M.; Stockham, T.L.; Poiser, K.R.; Kern, J.L.; Palaparthy, R.; Le, N.L.T.; Janicak, P. G. and Levy, N.A. Elimination of 7-aminoflunitrazepam and flunitrazepam in urine after a single dose of Rohypnol (2000) J. Forensic Sci., 45(5), 1031-1040.
116. Coller, J.K.; Somogyi, A.A. and Bochner, F. Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high-performance liquid chromatography (1998) J. Chromatogr. B, 719(1-2), 87-92.
117. Fisher, J.M.; Wrighton, S.A.; Watkins, P.B.; Schmiedlin-Ren, P.; Calamia, J.C.; Shen, D.D.; Kunze, K.L. and Thummel, K.E. Firstpass midazolam metabolism catalyzed by 1α,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers (1999) J. Pharmacol. Exp. Ther., 289(2), 1134-1142.
118. Eeckhoudt, S.L.; Horsmans, Y. and Verbeeck, R.K. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat (2002) Xenobiotica, 32(11), 975-984.
119. Shih, P.-S. and Huang, J.-D. Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes (2002) Drug Metab. Dispos., 30(12), 1491-1496.
120. Kharasch, E.D.; Walker, A.; Isoherranen, N.; Hoffer, C.; Sheffels, P.; Thummel, K.; Whittington, D. and Ensign, D. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam (2007) Clin. Pharmacol. Ther., 82(4), 410-426.
121. Hamaoka, N.; Oda, Y.; Hase, I. and Asada, A. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies (2001) Br. J. Anaesth., 86(4), 540-544.
122. Pinto Amar, G.; Wang, Y.-H.; Chalasani, N.; Skaar, T.; Kolwankar, D.; Gorski, J.C.; Liangpunsakul, S.; Hamman, M.A.; Arefayene, Million. and Hall, S.D. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression (2005) Clin. Pharmacol. Ther., 77(3), 178-188.
123. Gorski, J.C.; Jones, D.R.; Haehner-Daniels, B.D.; Hamman, M.A.; O'Mara, E.M. and Hall, S.D. The contribution of intestinal and hepatic CYP 3A to the interaction between midazolam and clarithromycin (1998) Clin. Pharmacol. Ther., 64(2), 133-143.
124. Quinney, S.K.; Haehner, B.D.; Rhoades, M.B.; Lin, Z.; Gorski, J.C. and Hall, S.D. Interaction between midazolam and clarithromycin in the elderly (2008) Br. J. Clin. Pharmacol., 65(1), 98-109.
125. Zhang, W.; Tan, T.M.C. and Lim, L.-Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats (2007) Drug Metab. Dispos., 35(1), 110-115.
126. Takedomi, S.; Matsuo, H.; Yamano, K.; Ohtani, H.; Sawada, Y. In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation (2001) J. Pharm. Pharmacol., 53(5), 643-651.
127. Oda, Y.; Mizutani, K.; Hase, I.; Nakamoto, T.; Hamaoka, N. and Asada, A. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro (1999) Br. J. Anaesth., 82(6), 900-903.
128. Quintieri, L.; Palatini, P.; Nassi, A.; Ruzza, P. and Floreani, M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes (2008) Biochem. Pharmacol., 75(6), 1426-1437.
129. Ahonen, J.; Olkkola, K.T.; Takala, A.; Neuvonen, P.J. Interaction between fluconazole and midazolam in intensive care patients (1999) Acta Anaesth. Scand., 43(5), 509-514.
130. Kashuba, A.D.; Nafziger, A.N.; Kearns, G.L.; Leeder, J.S.; Gotschall, R.; Rocci, M.L.Jr; Kulawy, R.W; Beck, D.J. and Bertino, J.S.Jr Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping (1998) Clin. Pharmacol. Ther., 64(3), 257-268.
131. Lam, Y.W.F.; Alfaro, C.L.; Ereshefsky, L.; Miller, M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone (2003) J. Clin. Pharmacol., 43(11), 1274-1282.
132. Veronese, M.L.; Gillen, L.P.; Burke, J.P.; Dorval, E.P.; Hauck, W.W.; Pequignot, E.; Waldman, S.A. and Greenberg, H.E. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice (2003) J. Clin. Pharmacol., 43(8), 831-839.
133. Mc Donnell, C.G.; Shorten, G. and Van Pelt, F.N.A.M. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro (2005) Anaesthesia, 60(8), 747-753.
134. Backman, J.T.; Kivisto, K.T.; Olkkola, K.T. and Neuvonen, P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin (1998) Eur. J. Clin. Pharmacol., 54(1), 53-58.
135. Tsunoda, S.M.; Velez, R.L.; Von Moltke, L.L. and Greenblatt, D.J. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole (1999) Clin. Pharmacol. Ther., 66(5), 461-471.
136. Ito, K.; Ogihara, K.; Kanamitsu, S.-I.; Itoh, T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes (2003) Drug Metab. Dispos., 31(7), 945-954.
137. Hamaoka, N.; Oda, Y.; Hase, I.; Mizutani, K.; Nakamoto, T.; Ishizaki, T. and Asada, A. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study (1999) Clin. Pharmacol. Ther., 66(2), 110-117.
138. Nakajima, M.; Suzuki, T.; Sasaki, T.; Yokoi, T.; Hosoyamada, A.; Yamamoto, T. and Kuroiwa, Y. Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans (1999) Ther. Drug Monit., 21(5), 507-513.
139. Huwyler, J.; Wright, M.B.; Gutmann, H. and Drewe, J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin (2006) Curr. Drug Metab., 7(2), 119-26.
140. Hosagrahara, V.P.; Hansen, L.K. and Remmel, R.P. Induction of the metabolism of midazolam by rifampin in cultured porcine hepatocytes: preliminary evidence for CYP3A isoforms in pigs (1999) Drug Metab. Dispos., 27(12), 1512-1518.
141. Wang, Z.; Gorski, J.C.; Hamman, M.A.; Huang, S.M.; Lesko, L.J. and Hall, S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity (2001) Clin. Pharmacol. Ther., 70(4), 317-326.
142. Qi, J.W.; Nakamura, K.; Hosokawa, S.; Okada, Y.; Horiuchi, R.; Yamamoto, K. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort (2005) Biol. Pharmaceut. Bull., 28(8), 1467-1471.
143. Backman, J.T.; Maenpaa, J.; Belle, D.J.; Wrighton, S.A.; Kivisto, K.T. and Neuvonen, P.J. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation (2000) Clin. Pharmacol. Ther., 67(4), 382-390.
144. Lilja, J.J.; Backman, J.T. and Neuvonen, P.J. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam-probes of CYP2C9, CYP1A2, and CYP3A4 (2007) Clin. Pharmacol. Ther., 81(6), 833-839.
145. Wang, J.-S.; Backman, J.T.; Kivisto, K.T. and Neuvonen, P.J. Effects of metronidazole on midazolam metabolism in vitro and in vivo (2000) Eur. J. Clin. Pharmacol., 56(8), 555-559.
146. Kashuba, A.D.M.; Bertino, J.S.Jr; Rocci, M.L.Jr; Kulawy, R.W.; Beck, D.J. and Nafziger, A.N. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam (1998) Clin. Pharmacol. Ther., 64(3), 269-277.
147. Kharasch, E.D.; Mautz, D.; Senn, T.; Lentz, G.; Cox, K. Menstrual cycle variability in midazolam pharmacokinetics (1999) J. Clin. Pharmacol., 39(3), 275-280.
148. Dostalek, M.; Jurica, J.; Pistovcakova, J.; Hanesova, M.; Tomandl, J.; Linhart, I. and Sulcova, A. Effect of methamphetamine on cytochrome P450 activity (2007) Xenobiotica, 37(12), 1355-1366.
149. Wang, J.-S.; Backman, J.T.; Kivisto, K.T. and Neuvonen, P.J. Effects of metronidazole on midazolam metabolism in vitro and in vivo (2000) Eur. J. Clin. Pharmacol., 56(8), 555-559.
150. Pentikis, H.S.; Connolly, M.; Trapnell, C.B.; Forbes, W.P. and Bettenhausen, D.K. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers (2007) Pharmacotherapy, 27(10), 1361-1369.
151. Johnson, T.N.; Rostami-Hodjegan, A.; Goddard, J.M.; Tanner, M. S. and Tucker, G.T. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis (2002) Br. J. Anaesth., 89(3), 428-437.
152. Boulieu, R.; Lehmann, B.; Salord, F.; Fisher, C. and Morlet, D. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients (1998) Eur. J. Drug Metab. Pharmakokinet., 23(2), 255-258.
153. Bodmer, M.; Link, B.; Grignaschi, N.; Kummer, O.; Ruegg, S.; Haschke, M. and Kraehenbuehl, S. Pharmacokinetics of Midazolam and Metabolites in a Patient With Refractory Status Epilepticus Treated With Extraordinary Doses of Midazolam (2008) Ther. Drug Monit., 30(1), 120-124.
154. Zhu, B.; Bush, D.; Doss, G.A.; Vincent, S.; Franklin, R.B. and Xu, S. (2008) Drug Metab. Dispos., 36(2), 331-338.
155. Klieber, S.; Hugla, S.; Ngo, R.; Arabeyre-Fabre, C.; Meunier, V.; Sadoun, F.; Fedeli, O.; Rival, M.; Bourrie, M.; Guillou, F.; Maurel, P. and Fabre, G. Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes (2008) Drug Metab. Dispos., 36(5), 851-862.
156. Reed, M.D.; Rodarte, A.; Blumer, J.L.; Khoo, K.-C.; Akbari, B.; Pou, S. and Kearns, G.L. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration (2001) J. Clin. Pharmacol., 41(12), 1359-1369.
157. de Wildt, S.N.; Kearns, G.L.; Hop, W.C.J.; Murry, D.J.; Abdel-Rahman, S.M. and van den Anker, J.N. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants (2001) Clin. Pharmacol. Ther., 70(6), 525-531.
158. Mulla, H.; McCormack, P.; Lawson, G.; Firmin, R.K. and Upton, D.R. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation (2003) Anesthesiology, 99(2), 275-282.
159. Knoester, P.D.; Jonker, D.M.; van der Hoeven, R.T.M.; Vermeij, T.A.C.; Edelbroek, P.M.; Brekelmans, G.J. and de Haan, G.J. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers (2002) Br. J. Clin. Pharmacol., 53(5), 501-507.
160. Odou, P.; Barthelemy, C.; Chatelier, D.; Luyckx, M.; Brunet, C.; Dine, T.; Gressier, B.; Cazin, M.; Cazin, J.C. and Robert, H. Pharmacokinetics of midazolam. Comparison of sublingual and intravenous routes in rabbit (1999) Eur. J. Drug Metab. Pharmakokinet, 24(1), 1-7.
161. Tsubo, T.; Sakai, I.; Okawa, H.; Ishihara, H. and Matsuki, A. Ketamine and midazolam kinetics during continuous hemodiafiltration in patients with multiple organ dysfunction syndrome (2001) Intens. Care Med., 27(6), 1087-90.
162. Swart, E.L.; de Jongh, J.; Zuideveld, K.P.; Danhof, M.; Thijs, L.G. and Strack van Schijndel, R.J.M. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration (2005) Am. J. Kidney Dis., 45(2), 360-371.
163. Eeckhoudt, S.L.; Desager, J.-P.; Horsmans, Y.; De Winne, A.J. and Verbeeck, R.K. Sensitive assay for midazolam and its metabolite hydroxymidazolam in human plasma by capillary high performance liquid chromatography (1998) J. Chromatogr. B, 710, 165-171.
164. Carrillo, J.A.; Ramos, S.I.; Agundez, J.A.; Martinez, C. and Benitez, J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A (1998) Ther. Drug Monit., 20(3), 19-24.
165. Link, B.; Haschke, M.; Wenk, M.; Krahenbuhl, S. Determination of midazolam and its hydroxymetabolites in human plasma and oral fluid by liquid chromatography/electrospray ionization ion trap tandem mass spectrometry (2007) Rapid Commun. Mass Spectrom., 21(9), 1531-1540.
166. Berman, M.E. and Taylor, S. The effects of triazolam on aggression in men (1995) Exp. Clin. Psychopharmacol., 3(4), 411-416.
167. Warrington, J.S.; Greenblatt, D.J. and Von Moltke, L.L. Role of CYP3A enzymes in the biotransformation of triazolam in rat liver (2004) Xenobiotica, 34(5), 463-471.
168. Arayne, M.S.; Sultana, N. and Bibi, Z. Grapefruit juice - drug interactions (2005) Pak. J. Pharm. Sci., 18(4), 45-57.
169. Sugimoto, K.; Araki, N.; Ohmori, M.; Harada, K.; Cui, Y.; Tsuruoka, S.; Kawaguchi, A. and Fujimura, A. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam (2006) Eur. J. Clin. Pharmacol., 62(3), 209-215.
170. Lilja, J.J.; Kivisto, K.T.; Backman, J.T.; Neuvonen, P.J. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life (2000) Eur. J. Clin. Pharmacol., 56(5), 411-415.
171. Shinozuka, T.; Kurihara, K.; Yamamoto, K.; Tanaka, E. and Terada, M. Reactivity of various recombinant human cytochrome P450 isoforms for hydroxylation of triazolam in vitro (2005) Jpn. J. Forensic Toxicol., 23(3), 205-208.
172. Patki, K.C.; von Moltke, L.L. and Greenblatt, D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5 (2003) Drug Metab. Dispos., 31(7), 938-944.
173. Niemi, M.; Backman, J.T.; Fromm, M.F.; Neuvonen, P.J.; Kivisto, K.T. Pharmacokinetic interactions with rifampicin: Clinical relevance (2003) Clin. Pharmakokinet., 42(9), 819-850.
174. Greenblatt, D.J.; von Moltke, L.L.; Harmatz, J.S.; Durol, A.L.B.; Daily, J.P.; Graf, J.A.; Mertzanis, P.; Hoffman, J.L. and Shader, R.I. Differential impairment of triazolam and zolpidem clearance by ritonavir (2000) J. AIDS - J. Acquire Immun. Deffic. Syndr., 24(2), 129-136.
175. von Moltke, L.L.; Durol, A.L.; Duan, S.X. and Greenblatt, D.J. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole (2000) Eur. J. Clin. Pharmacol., 56(3), 259-261.
176. von Moltke, L.L.; Greenblatt, D.J.; Granda, B.W.; Giancarlo, G.M.; Duan, S.X.; Daily, J.P.; Harmatz, J.S. and Shader, R.I. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors (2001) J. Clin. Pharmacol., 41(1), 85-91.
177. Greenblatt, D.J.; Von Moltke, L.L.; Harmatz, J.S.; Counihan, M.; Graf, J.A.; Durol, A.L.B.; Mertzanis, P.; Duan, S.X.; Wright, C.E. and Shader, R.I. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences (1998) Clin. Pharmacol. Ther., 64(3), 278-285.
178. Von Moltke, L.L.; Greenblatt, D.J.; Duan, S.X.; Harmatz, J.S. and Shader, R.I. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in-vitro (1998) Pharm. Pharmacol. Commun., 4(9), 443-445.
179. Robertson, P. Jr; Hellriegel, E.T.; Arora, S. and Nelson, M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers (2002) Clin. Pharmacol. Ther., 71(1), 46-56.
180. O'Connor-Semmes, R.L.; Kersey, K.; Williams, D.H.; Lam, R. and Koch, K.M. Effect of ranitidine on the pharmacokinetics of triazolam and α-hydroxytriazolam in both young (19-60 years) and older (61-78 years) people (2001) Clin. Pharmacol. Ther., 70(2), 126-131.
181. Lin, D.-L.; Huang, T.-Y.; Liu, H.-C. and Yin, R.-M. Urinary Excretion of α-Hydroxytriazolam Following a Single Dose of Halcion (2005) J. Anal. Toxicol., 29(2), 118-123.
182. Tsujikawa, K.; Kuwayama, K.; Miyaguchi, H.; Kanamori, T.; Iwata, Y.; Inoue, H. and Kishi, T. Urinary Excretion Profiles of Two Major Triazolam Metabolites, -Hydroxytriazolam and 4-Hydroxytriazolam (2005) J. Anal. Toxicol., 29(4), 240-243.
183. Gaillard, Y., Gay-Montchamp, J.P. and Ollagnier, M. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorus detection after solid-phase extraction (1993) J. Chromatogr., 622(2), 197-208.
184. Moore, C.; Coulter, C.; Crompton, K. and Zumwalt, M. Determination of Benzodiazepines in Oral Fluid Using LC-MS-MS (2007) J. Anal. Toxicol., 31(9), 596-600.
185. Ngwa, G.; Fritch, D.; Blum, K. and Newland, G. Simultaneous Analysis of 14 Benzodiazepines in Oral Fluid by Solid-Phase Extraction and LC-MS-MS (2007) J. Anal. Toxicol., 31(7), 369-376.
186. Gil Tejedor, A.M.; Fernandez Hernando, P. and Durand Alegria, J.S. A rapid fluorimetric screening method for the 1,4-benzodiazepines: Determination of their metabolite oxazepam in urine (2007) Anal. Chim. Acta, 591(1), 112-115.
187. Samanidou, V.F.; Pechlivanidou, A.P. and Papadoyannis, I.N. Development of a validated HPLC method for the determination of four 1,4-benzodiazepines in human biological fluids (2007) J. Sep. Sci., 30(5), 679-687.
188. Blas, M.; McCord, B.R. Determination of trace levels of benzodiazepine in urine using capillary electrochromatography-time of flight mass spectrometry (2008) Electrophoresis, 29(10), 2182-2192.
189. Anderson, R.A.; Ariffin, M.M.; Cormack, P.A.G. and Miller, E.I. Comparison of molecularly imprinted solid-phase extraction (MISPE) with classical solid-phase extraction (SPE) for the detection of benzodiazepines in post-mortem hair samples (2008) Forensic Sci. Int., 174(1), 40-46.
190. Mercolini, L.; Mandrioli, R.; Amore, M. and Raggi, M.A. Separation and HPLC analysis of fifteen benzodiazepines in human plasma (2008) J. Sep. Sci., 31(14), 2619-2626.